109 related articles for article (PubMed ID: 21969006)
1. Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line.
Dizaji MZ; Malehmir M; Ghavamzadeh A; Alimoghaddam K; Ghaffari SH
Neurochem Res; 2012 Feb; 37(2):370-80. PubMed ID: 21969006
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of silymarin in glioblastoma cancer cells through redox system regulation.
Zarei Shandiz S; Erfani B; Hashemy SI
Mol Biol Rep; 2024 Jun; 51(1):723. PubMed ID: 38833199
[TBL] [Abstract][Full Text] [Related]
3. The importance of integrated therapies on cancer: Silibinin, an old and new molecule.
Roca E; Colloca G; Lombardo F; Bellieni A; Cucinella A; Madonia G; Martinelli L; Damiani ME; Zampieri I; Santo A
Oncotarget; 2024 May; 15():345-353. PubMed ID: 38781107
[TBL] [Abstract][Full Text] [Related]
4. Silibinin suppresses glioblastoma cell growth, invasion, stemness, and glutamine metabolism by YY1/SLC1A5 pathway.
Liu M; Liu X; Qiao J; Cao B
Transl Neurosci; 2024 Jan; 15(1):20220333. PubMed ID: 38410123
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Mechanism of Flavonoids on High-Grade Adult-Type Diffuse Gliomas.
Wong SC; Kamarudin MNA; Naidu R
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839156
[TBL] [Abstract][Full Text] [Related]
6. Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration.
Mitra S; Dash R; Munni YA; Selsi NJ; Akter N; Uddin MN; Mazumder K; Moon IS
Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422293
[TBL] [Abstract][Full Text] [Related]
7. Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.
Yu M; Zhang Y; Fang M; Jehan S; Zhou W
Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456577
[TBL] [Abstract][Full Text] [Related]
8. Honokiol attenuate the arsenic trioxide-induced cardiotoxicity by reducing the myocardial apoptosis.
Huang AL; Yang F; Cheng P; Liao DY; Zhou L; Ji XL; Peng DD; Zhang L; Cheng TT; Ma L; Xia XG
Pharmacol Res Perspect; 2022 Apr; 10(2):e00914. PubMed ID: 35171536
[TBL] [Abstract][Full Text] [Related]
9. Neuroimmunomodulatory Properties of Flavonoids and Derivates: A Potential Action as Adjuvants for the Treatment of Glioblastoma.
do Nascimento RP; Dos Santos BL; Amparo JAO; Soares JRP; da Silva KC; Santana MR; Almeida ÁMAN; da Silva VDA; Costa MFD; Ulrich H; Moura-Neto V; Lopes GPF; Costa SL
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057010
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs.
Zhai K; Mazurakova A; Koklesova L; Kubatka P; Büsselberg D
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944485
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide as a novel anti-glioma drug: a review.
Fang Y; Zhang Z
Cell Mol Biol Lett; 2020; 25():44. PubMed ID: 32983240
[TBL] [Abstract][Full Text] [Related]
12. Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity.
Delmas D; Xiao J; Vejux A; Aires V
Molecules; 2020 Apr; 25(9):. PubMed ID: 32344919
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin.
Darzi S; Mirzaei SA; Elahian F; Shirian S; Peymani A; Rahmani B; Dibazar SP; Aali E
Evid Based Complement Alternat Med; 2019; 2019():3291737. PubMed ID: 31814840
[TBL] [Abstract][Full Text] [Related]
14. The embryonic transcription factor Brachyury confers chordoma chemoresistance via upregulating CA9.
Jian J; Zhong N; Jiang D; Li L; Lou Y; Zhou W; Chen S; Xiao J
Am J Transl Res; 2018; 10(3):936-947. PubMed ID: 29636883
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis.
Moloudi K; Neshasteriz A; Hosseini A; Eyvazzadeh N; Shomali M; Eynali S; Mirzaei E; Azarnezhad A
Iran Biomed J; 2017 Sep; 21(5):330-7. PubMed ID: 28459147
[TBL] [Abstract][Full Text] [Related]
16. Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles.
Pistollato F; Bremer-Hoffmann S; Basso G; Cano SS; Elio I; Vergara MM; Giampieri F; Battino M
Target Oncol; 2016 Feb; 11(1):1-16. PubMed ID: 26275397
[TBL] [Abstract][Full Text] [Related]
17. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
18. KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Woo SR; Ham Y; Kang W; Yang H; Kim S; Jin J; Joo KM; Nam DH
Biomed Res Int; 2014; 2014():747415. PubMed ID: 25295271
[TBL] [Abstract][Full Text] [Related]
19. Autophagy interplays with apoptosis and cell cycle regulation in the growth inhibiting effect of Trisenox in HEP-2, a laryngeal squamous cancer.
Pereira DL; Dos Santos Ferreira AC; de Faria GP; Kwee JK
Pathol Oncol Res; 2015 Jan; 21(1):103-11. PubMed ID: 24838151
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
